Cell line · CVCL_1054
Papers42
1 to 20 of 42
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PubMed 42997835 | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Triptolide in Combination with the Gli1 Inhibitor GANT61 Eradicates Anaplastic Thyroid Cancer by Suppressing Cancer Stem Cell Self-Renewal and Enhancing Apoptosis and Pyroptosis. | Int J Biol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SUMOylation-Dependent Repression of BIRC7 by DNMT3a Suppresses Papillary Thyroid Carcinoma Progression. | Cell Biochem Funct | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of CSE couples with BRAF V600E to fuel thyroid cancer metastatic progression through zinc-dependent activation of the EMT machinery. | J Exp Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Modulation of chemokine secretion and oxidative stress in vitro in thyroid cells after exposure to thiocyanate, nitrate, or perchlorate. | Front Endocrinol (Lausanne) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Roundup® Original DI promotes proliferation in papillary thyroid carcinoma cells: a comparative study highlighting cell-type-dependent effects. | Front Endocrinol (Lausanne) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An ICAM1-Targeting Chimeric Costimulatory Receptor Mimics the Immune Synapse and Enhances Tumor-Specific T-cell Function. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Bisphenol A Induces DNA Damage and Differential Cytotoxicity in Thyroid Cells: High-Dose Effects Challenge Regulatory Thresholds. | J Appl Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| AURKB and PI3K/AKT/mTOR pathways converge to regulate TERT expression. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Focal adhesion kinase promotes ribosome biogenesis to drive advanced thyroid cancer cell growth and survival. | Front Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| B7H6 is the predominant activating ligand driving natural killer cell-mediated killing in patients with liquid tumours: evidence from clinical, in silico, in vitro, and in vivo studies. | EBioMedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. | Cancer Biol Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. | Mol Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype. | Br J Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Targeting non-canonical pathways as a strategy to modulate the sodium iodide symporter. | Cell Chem Biol | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer. | Front Cell Dev Biol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. | Nat Commun | 2019 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1054/papers